PharmAust Limited (PAA.AX)
- Previous Close
0.2350 - Open
0.2350 - Bid 0.2550 x 34484800
- Ask 0.2550 x 33874700
- Day's Range
0.2350 - 0.2600 - 52 Week Range
0.0655 - 0.5350 - Volume
1,820,798 - Avg. Volume
1,579,288 - Market Cap (intraday)
98.754M - Beta (5Y Monthly) 1.27
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0200 - Earnings Date Feb 29, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
PharmAust Limited develops targeted cancer therapeutics for humans and animals in Switzerland, Australia, Sweden, the United States, and internationally. The company develops drug discovery intellectual property for the treatment of various cancers, neurological diseases, and viral infections. Its lead candidate is Monepantel (MPL), a small molecule drug which is in Phase II clinical trials for the treatment of cancer. The company also provides products and services in synthetic and medicinal chemistry to the drug discovery and pharmaceutical industries worldwide. It serves drug discovery and pharmaceutical industries. PharmAust Limited was incorporated in 2000 and is based in Bentley, Australia.
www.pharmaust.comRecent News: PAA.AX
Performance Overview: PAA.AX
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PAA.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PAA.AX
Valuation Measures
Market Cap
98.75M
Enterprise Value
97.10M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
13.23
Enterprise Value/Revenue
34.38
Enterprise Value/EBITDA
-11.37
Financial Highlights
Profitability and Income Statement
Profit Margin
-177.28%
Return on Assets (ttm)
-31.99%
Return on Equity (ttm)
-101.98%
Revenue (ttm)
3.71M
Net Income Avi to Common (ttm)
-7.75M
Diluted EPS (ttm)
-0.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
5.45M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-898.99k
Company Insights: PAA.AX
PAA.AX does not have Company Insights